Infectious Disease
According to studies, J&J vaccine protects against delta variant for at least 8 months
Source / information
Published by:
Disclosure:
Mammen and Stoffels are Johnson & Johnson employees.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
Data from two preprint studies showed that Johnson & Johnson’s single-dose COVID-19 vaccine produced “strong, sustained activity” against worrying SARS-CoV-2 variants, including the rapidly spreading delta variant, reported the enterprise.
The results were reported in a press release and the studies were transmitted to the preprint server bioRxiv.
Johnson & Johnson’s COVID-19 vaccine produces “strong, sustained activity” against the rapidly spreading Delta variant, the company said. Source: Adobe Stock.
“The studies announced today confirm the ability of the Johnson & Johnson COVID-19 vaccine to protect the health of people around the world,” said Johnson & Johnson Chief Scientific Officer Paul Stoffels, MD, said in the publication. “We believe that our vaccine offers permanent protection against COVID-19 and triggers neutralizing activity against the Delta variant. This complements the solid clinical data that supports our single vaccine’s ability to protect against multiple worrying variants. “
Data demonstrating the vaccine’s effectiveness against variants comes from a preprint study that examined blood samples from a subset of eight participants in the Phase 3 ENSEMBLE study, which showed the shot had neutralizing antibody activity against the Delta variant “Even higher” triggered higher than what was recently observed for the beta variant (B.1.351) in South Africa, “said Johnson & Johnson. According to the study, the vaccine was 85% effective against serious illness, protecting against hospitalization and death.
A second preprint study showed that the vaccine “produced a strong neutralizing antibody response that did not subside,” but improved over time for at least 8 months. Mathai Moms, MD, PhD, The global head of research and development at Janssen, the Johnson & Johnson subsidiary that developed the vaccine, said in the release.
“With each new data set, we build on our solid evidence that our unique COVID-19 vaccine is playing a critical role in ending the pandemic that continues to evolve and pose new challenges for global health,” said Mammen.
References:
perspective
Back to top
Amesh A. Adalja, MD
Many of us have been waiting for data on the effectiveness of the Johnson & Johnson vaccine, especially against variants. I was one who expected that we would get good news with this vaccine, and that seems to be the case. Hopefully this should dampen the notion that people who have been vaccinated with this highly potent vaccine will somehow need a booster with a different version of the vaccine. Of course, real-world clinical data will help us fully understand the protection this vaccine provides. At this point in time, I don’t think people should be suggesting that booster vaccinations are needed and people who have received those vaccines as there is no data to suggest it is needed.
Amesh A. Adalja, MD
Senior scholarship holder
Johns Hopkins Center for Health Safety
Disclosure: Adalja does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
